Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C33H49NO10S |
Molecular Weight | 651.808 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS(O)(=O)=O)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])C[C@H](C)C4=CC(=O)C=C[C@]34C
InChI
InChIKey=PSCNNGGPKIBAHB-WFVOKNHCSA-N
InChI=1S/C33H49NO10S/c1-21-17-23-24-12-14-33(40,32(24,3)19-26(36)30(23)31(2)13-11-22(35)18-25(21)31)27(37)20-44-29(39)10-8-6-5-7-9-28(38)34(4)15-16-45(41,42)43/h11,13,18,21,23-24,26,30,36,40H,5-10,12,14-17,19-20H2,1-4H3,(H,41,42,43)/t21-,23-,24-,26-,30+,31-,32-,33-/m0/s1
DescriptionSources: http://www.drugbank.ca/drugs/DB00959Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/medrol.html
Sources: http://www.drugbank.ca/drugs/DB00959
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/medrol.html
Methylprednisolone is a prednisolone derivative with similar anti-inflammatory and immunosuppressive action. It is adjunctive therapy for short-term administration in rheumatoid arthritis. It is indicated in the following conditions: endocrine disorders, rheumatic disorders, collagen diseases, allergic states etc. Methylprednisolone is marketed in the USA and Canada under the brand names Medrol and Solu-Medrol. Methylprednisolone is a GR receptor agonist.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800003722
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00959 |
2.4 nM [EC50] | ||
Target ID: CHEMBL2034 Sources: http://www.ampoule.org.hk/pdf/advantan.pdf |
|||
Target ID: CHEMBL2111332 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15329590 |
1.07 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MEDROL Approved UseINDICATIONS AND USAGE
MEDROL Tablets are indicated in the following conditions:
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Synovitis of osteoarthritis
Acute nonspecific tenosynovitis
Post-traumatic osteoarthritis
Psoriatic arthritis
Epicondylitis
Acute gouty arthritis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Severe seborrheic dermatitis
Exfoliative dermatitis
Mycosis fungoides
Pemphigus
Severe psoriasis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis
Drug hypersensitivity reactions
Serum sickness
Contact dermatitis
Bronchial asthma
Atopic dermatitis
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Sympathetic ophthalmia
Keratitis
Optic neuritis
Allergic conjunctivitis
Chorioretinitis
Iritis and iridocyclitis
7. Respiratory Diseases
Symptomatic sarcoidosis
Berylliosis
Loeffler's syndrome not manageable by other means
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
Trichinosis with neurologic or myocardial involvement. Launch Date1957 |
|||
Primary | MEDROL Approved UseINDICATIONS AND USAGE
MEDROL Tablets are indicated in the following conditions:
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Synovitis of osteoarthritis
Acute nonspecific tenosynovitis
Post-traumatic osteoarthritis
Psoriatic arthritis
Epicondylitis
Acute gouty arthritis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Severe seborrheic dermatitis
Exfoliative dermatitis
Mycosis fungoides
Pemphigus
Severe psoriasis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis
Drug hypersensitivity reactions
Serum sickness
Contact dermatitis
Bronchial asthma
Atopic dermatitis
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Sympathetic ophthalmia
Keratitis
Optic neuritis
Allergic conjunctivitis
Chorioretinitis
Iritis and iridocyclitis
7. Respiratory Diseases
Symptomatic sarcoidosis
Berylliosis
Loeffler's syndrome not manageable by other means
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
Trichinosis with neurologic or myocardial involvement. Launch Date1957 |
|||
Primary | MEDROL Approved UseINDICATIONS AND USAGE
MEDROL Tablets are indicated in the following conditions:
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Synovitis of osteoarthritis
Acute nonspecific tenosynovitis
Post-traumatic osteoarthritis
Psoriatic arthritis
Epicondylitis
Acute gouty arthritis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Severe seborrheic dermatitis
Exfoliative dermatitis
Mycosis fungoides
Pemphigus
Severe psoriasis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis
Drug hypersensitivity reactions
Serum sickness
Contact dermatitis
Bronchial asthma
Atopic dermatitis
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Sympathetic ophthalmia
Keratitis
Optic neuritis
Allergic conjunctivitis
Chorioretinitis
Iritis and iridocyclitis
7. Respiratory Diseases
Symptomatic sarcoidosis
Berylliosis
Loeffler's syndrome not manageable by other means
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
Trichinosis with neurologic or myocardial involvement. Launch Date1957 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
213 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12174030 |
32 mg single, intravenous dose: 32 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLPREDNISOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
931 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12174030 |
32 mg single, intravenous dose: 32 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLPREDNISOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.3 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12174030 |
32 mg single, intravenous dose: 32 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLPREDNISOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23% |
METHYLPREDNISOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1000 mg/kg single, intravenous Highest studied dose Dose: 1000 mg/kg Route: intravenous Route: single Dose: 1000 mg/kg Sources: |
unhealthy, 0-15 years n = 26 Health Status: unhealthy Condition: sickle cell disease Age Group: 0-15 years Sex: M+F Population Size: 26 Sources: |
|
1250 mg 1 times / day multiple, oral Highest studied dose Dose: 1250 mg, 1 times / day Route: oral Route: multiple Dose: 1250 mg, 1 times / day Sources: |
unhealthy, 18–59 years n = 24 Health Status: unhealthy Condition: multiple sclerosis relapse Age Group: 18–59 years Sex: M+F Population Size: 24 Sources: |
|
120 mg 1 times / week multiple, intramuscular Highest studied dose Dose: 120 mg, 1 times / week Route: intramuscular Route: multiple Dose: 120 mg, 1 times / week Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubs.acs.org/doi/abs/10.1021/mp900163d Page: - |
no | |||
Page: - |
yes | |||
Page: - |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
yes | |||
Page: - |
yes | |||
Sources: http://epubs.surrey.ac.uk/855783/1/27606608.pdf Page: - |
yes | |||
Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Corticosteroids for acute severe asthma in hospitalised patients. | 2001 |
|
Sensorineural hearing loss in conjunction with aortic insufficiency in systemic lupus erythematosus. | 2001 |
|
Reversible posterior leukoencephalopathy in a patient with minimal-change nephrotic syndrome. | 2001 Apr |
|
Lupus nephritis in a child with AIDS. | 2001 Apr |
|
Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus. | 2001 Apr |
|
Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins. | 2001 Feb |
|
Initial remission-inducing effect of very low-dose cyclosporin monotherapy for minimal-change nephrotic syndrome in Japanese adults. | 2001 Feb |
|
Severe renal impairment in the case of classic polyarteritis nodosa. | 2001 Feb |
|
Three cases of C-ANCA-positive vasculitis treated with immunoadsorption: possible benefit in early treatment. | 2001 Feb |
|
Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis. | 2001 Feb |
|
Steroid-resistant kidney transplant rejection: diagnosis and treatment. | 2001 Feb |
|
Selective involvement of the choroid plexus on cerebral magnetic resonance images: a new radiological sign in patients with systemic lupus erythematosus with neurological symptoms. | 2001 Feb |
|
[Contact allergy caused by poison ivy (Toxicodendron spp]. | 2001 Feb |
|
Lupus nephritis in children: prognostic significance of clinicopathological findings. | 2001 Feb |
|
[Psychological and behavioral disorders with good outcome in neurosarcoidosis]. | 2001 Feb |
|
[Value of abdominal-pelvic computed tomography in adult rheumatoid purpura]. | 2001 Feb |
|
Preliminary results of a prospective randomized study of basiliximab in kidney transplantation. | 2001 Feb-Mar |
|
Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation. | 2001 Feb-Mar |
|
Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation. | 2001 Feb-Mar |
|
Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation. | 2001 Feb-Mar |
|
Daclizumab induction therapy in combination with tacrolimus. | 2001 Feb-Mar |
|
Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. | 2001 Feb-Mar |
|
Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation. | 2001 Feb-Mar |
|
Successful withdrawal of steroid after renal transplantation. | 2001 Feb-Mar |
|
Prevention of bone loss in kidney graft recipients. | 2001 Feb-Mar |
|
Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients. | 2001 Feb-Mar |
|
Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. | 2001 Feb-Mar |
|
Addition of steroids blocks the tolerogenic potential of donor-specific blood transfusion. | 2001 Feb-Mar |
|
Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue. | 2001 Jan |
|
A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease. | 2001 Jan |
|
Recurrent orbital inflammation from metastatic orbital carcinoid tumor. | 2001 Mar |
|
[Intramural hematoma of the large intestine caused by cytomegalovirus vasculitis in a patient with SLE]. | 2001 Mar |
|
Pulmonary function in men after repeated sessions of oxygen breathing at 0.25 MPa for 90 min. | 2001 Mar |
|
[Value of methylprednisolone perfusions in the corticodependent forms of Horton's disease]. | 2001 Mar |
|
[Acute myelitis of an unusual cause in a child: the lymphocytic choriomeningitis virus]. | 2001 Mar |
|
Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes. | 2001 Mar |
|
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. | 2001 Mar |
|
Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. | 2001 Mar |
|
Chronic eosinophilic pneumonia presenting with recurrent massive bilateral pleural effusion : case report. | 2001 Mar |
|
Systemic glucocorticoids in severe exacerbations of COPD. | 2001 Mar |
|
Steroids for acute exacerbations of COPD : how long is enough? | 2001 Mar |
|
Methylprednisolone does not benefit patients undergoing coronary artery bypass grafting and early tracheal extubation. | 2001 Mar |
|
Intrathecal methylprednisolone for postherpetic neuralgia. | 2001 Mar 29 |
|
Intrathecal methylprednisolone for postherpetic neuralgia. | 2001 Mar 29 |
|
Intrathecal methylprednisolone for postherpetic neuralgia. | 2001 Mar 29 |
|
Intrathecal methylprednisolone for postherpetic neuralgia. | 2001 Mar 29 |
|
Intrathecal methylprednisolone for postherpetic neuralgia. | 2001 Mar 29 |
|
Intrathecal methylprednisolone for postherpetic neuralgia. | 2001 Mar 29 |
|
[Comparison of two different treatments of lateral humeral epicondylitis--"tennis elbow". A randomized controlled trial]. | 2001 Mar 5 |
|
Prospective experience with a 20-gauge Tuohy needle for lumbar epidural steroid injections: Is confirmation with fluoroscopy necessary? | 2001 Mar-Apr |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/medrol.html
Each Medrol Tablet (methylprednisolone) for oral administration contains 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of methylprednisolone. The initial dosage of Medrol Tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26339357
Treatment with methylprednisolone concentrations above 50 uM could ignificantly reduce the proliferation activity of human CLL cell line MEC-1 by 23.34%, 30.73%, 30.57% after 24 h, and 28.48%, 42.35%, 44.56% after 48 h respectively
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
156480
Created by
admin on Sat Dec 16 11:23:06 GMT 2023 , Edited by admin on Sat Dec 16 11:23:06 GMT 2023
|
PRIMARY | |||
|
56068
Created by
admin on Sat Dec 16 11:23:06 GMT 2023 , Edited by admin on Sat Dec 16 11:23:06 GMT 2023
|
PRIMARY | |||
|
Methylprednisolone suleptanate
Created by
admin on Sat Dec 16 11:23:06 GMT 2023 , Edited by admin on Sat Dec 16 11:23:06 GMT 2023
|
PRIMARY | |||
|
121807-10-1
Created by
admin on Sat Dec 16 11:23:06 GMT 2023 , Edited by admin on Sat Dec 16 11:23:06 GMT 2023
|
PRIMARY | |||
|
3O5T2NJE2D
Created by
admin on Sat Dec 16 11:23:06 GMT 2023 , Edited by admin on Sat Dec 16 11:23:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD